Angiogenesis is the formation of new blood vessels from pre-existing vasculature. Pathologic angiogenesis in the eye can lead to severe visual impairment. In our review, we discuss the roles of both pro-angiogenic and anti-angiogenic molecular players in corneal angiogenesis, proliferative diabetic retinopathy, exudative macular degeneration and retinopathy of prematurity, highlighting novel targets that have emerged over the past decade.
Introduction
Neovascularization (NV) is the formation of new blood vessels in previously avascular tissues by way of vasculogenesis and angiogenesis. Vasculogenesis is the formation of new blood vessels from bone marrow-derived angioblasts and is usually seen during embryogenesis. On the other hand, angiogenesis is the formation of new blood vessels from preexisting vasculature (Beck and D'Amore 1997; Isner and Asahara 1999) with an established role in tumour metastasis, corneal and retinal neovascular disorders (Folkman 1995) .
Angiogenesis is the result of a complex interplay between growth factors, vascular endothelial cells, extracellular matrix molecules, chemokines and cell signalling molecules. It involves vascular endothelial cell activation, proteolytic endothelial basement membrane degradation, extracellular matrix degradation, endothelial cell migration, vascular proliferation, formation of tight junctions, recruitment of pericytes, and deposition of new basement membrane, closing off the newly formed arteriovenous collateral vessels (Folkman 1971; Yancopoulos et al. 2000; Carmeliet 2003) .
Ocular angiogenesis can lead to irreversible visual impairment whether it is by opacification of the cornea or permanent deleterious changes to the neuronal architecture of the retina. This necessitates early and aggressive *For correspondence. E-mail: bala.ambati@utah.edu. management of ocular neovascular conditions, possibly best done by targeting multiple putative factors. In our review, we explore these mediators of ocular angiogenesis and their roles in corneal neovascularization (KNV), proliferative diabetic retinopathy (PDR), exudative age-related macular degeneration (wet AMD) and retinopathy of prematurity (ROP).
Corneal neovascularization
Ocular surface disease, especially those leading to KNV poses a serious public health concern with considerable morbidity. The incidence of KNV in US stands at a grand 1.4 million with 4% of the population suffering from the condition (Lee et al. 1998) . The dreaded complications of KNV include corneal oedema, lipid deposition, scarring and reduced chances of successful corneal grafts. Thirty per cent of vascularized corneas face the risk of graft failure following penetrating keratoplasty, making it imperative to identify the molecular mechanisms that may be targeted to prevent or retard its progression (Cursiefen et al. 1998) .
The cornea bears an 'angiogenic privilege' and is avascular allowing maximal entry of incident light. This angiogenic privilege is maintained by a fine balance between anti-angiogenic factors and angiogenic factors in the cornea (Hanahan and Folkman 1996) . Insults of chemical, mechanical, degenerative or infectious nature can trigger inflamma-tory and immune-mediated pathways which upregulate expression of VEGF (vascular endothelial growth factor), the key player in KNV, and its signalling cascades. Table 1 lists diseases which are associated with KNV.
Blood supply to the cornea originates from the ophthalmic artery which branches into the ciliary arteries and these arteries further divide to form the pericorneal limbal plexus. In corneal angiogenesis, neovessels arise from this pericorneal plexus (Burger et al. 1985; Yaylali et al. 1998) and sprout into the stroma. Depending on the underlying pathology, these blood vessels can either grow into the stroma in conditions such as viral stromal keratitis or form a vascular pannus which is more commonly seen in ocular surface disorders . Initial events in KNV as studied in rat corneas following chemical cautery involve vasodilation of the limbal vessels and leucocytosis. By 27 h, vascular buds emerge from the pericorneal venules and capillaries which lengthen, multiply and anastomose to form a network of blood vessels by day three. These vessels reach the site of injury by day seven and redundant vessels regress by day 14 leaving large tortuous vessels that merge with a pericorneal artery or vein (Burger et al. 1983) . In human corneas, KNV commonly extends into the upper and middle third of the stroma (Cursiefen et al. 1998) .
Several factors are known to play a role in KNV, among which we shall briefly discuss VEGF, basic fibroblast growth factor (bFGF), matrix metalloproteinases (MMPs), angiostatin, endostatin, pigment epithelium derived factor (PEDF) and review novel therapeutic targets uncovered in the past decade. A comprehensive list of the mediators of KNV is summarized in table 2.
Vascular endothelial growth factor
The VEGF family forms a part of the platelet-derived growth factor (PDGF) supergene family members of the VEGF family comprise VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E and PlGF (placental growth factor). These cytokines bind to cell-surface receptors that belong to the family of tyrosine-kinase receptors (Shibuya and ClaessonWelsh 2006) . VEGF-A has been studied extensively and plays a critical role in both vasculogenesis and angiogenesis (Hiratsuka et al. 2005; Sakurai et al. 2005; Takahashi and Shibuya 2005) . VEGF is a secreted peptide found extensively in the epithelium of vascularized corneas secondary to inflammation (Kvanta 2006) and is a potent stimulator of hypoxia-induced corneal inflammation and angiogenesis . When the inflammatory cascade is interrupted preventing chemotaxis and endothelial migration, it is seen to remarkably inhibit KNV as observed in CCR2 and CCR5 genetic ablative murine models (Ambati et al. 2003a,b) . Alternative splicing of the VEGF gene yields five isoforms, VEGF115, VEGF121, VEGF165, VEGF189 and VEGF206 (Sugihara et al. 1998) . VEGF is secreted by macrophages, T cells, retinal pigment epithelial (RPE) cells, astrocytes, pericytes and smooth muscle cells in response to hypoxic and inflammatory stimuli. VEGF binds to tyrosine-kinase receptors, VEGFR1 (Flt-1) and VEGFR2 (Flk-1), and also the neuropilins which lack tyrosine-kinase activity. VEGF signalling is modulated by angiopoietins that bind to Tie-2 receptors (Campochiaro 2004) . Soluble Tie-2 receptors curb and regress KNV independent of VEGF in murine models of mechanical-alkali injury-induced KNV (Singh et al. 2005b) . The avascular cornea owes it transparency to soluble VEGFR-1 (sFlt-1) that acts as a decoy receptor for VEGF-A, a potent stimulator of KNV . Gene therapy with VEGFR-1 is antiangiogenic when injected intracorneally in murine models of KNV (Singh et al. 2005a Jani et al. 2007 ). Based on this evidence, using gene therapy to target specific receptors and proangiogenic molecules holds promise (Campochiaro 2006) .
Fibroblast growth factor
Basic FGF (bFGF) belongs to the fibroblast growth family that encompasses 23 structurally related heparin-binding angiogenic peptides (Shing et al. 1984 (Shing et al. , 1985 Itoh and Ornitz 2004) . FGFs are pleiotropic factors that act on various cells including endothelial cells. They interact with heparinsulphate proteoglycans (HSPGs) and FGF receptors (FGFR-1, FGFR-2, FGFR-3, FGFR-4) like VEGF receptors bear tyrosine-kinase activity. It is perhaps their interaction with HSPGs that makes extracellular matrix (ECM) a key player in the regulation of angiogenesis. FGFs bind to their receptors found on target cells (Presta et al. 2005) . FGF-1 and FGF-2 have been investigated extensively in noninflammatory KNV. FGF-1 is expressed in the normal corneal epithelium whereas FGF-2 is overexpressed after injury (Soubrane et al. 1990) . Upon binding with their angiogenic ligands (FGF-1, FGF-2 and FGF-4), FGFRs are autophosphorylated leading to activation of several intracellular signalling pathways leading to the recruitment of Shc, FRS2 and Crk adaptor molecules (Cross and Claesson-Welsh 2001) . Induction of endothelial cell proliferation by FGF leading to angiogenesis involves not only the activation of the mitogen-activated protein (MAP) kinase pathway, but also sustained activation of protein kinase C (PKC) (Presta et al. 1991) . The angiogenic FGFs further promote angiogenesis by causing ECM degradation. FGF-1, FGF-2 and FGF-4 upregulate urokinase-type plasminogen activator (uPA) and MMP production in endothelial cells allowing localized proteolytic digestion at the vascular migration front (Mignatti and Rifkin 2000) . However, this process is kept in check by the induction of plasminogen activator inhibitor (PAI)-1 providing fine control of the enzymatic ECM degradation (Kaneko et al. 2002) .
Once the path for cell migration has been carved, FGF-1, FGF-2, FGF8b isoform and FGF-10 promote chemotaxis in endothelial cells (Stokes et al. 1990; Mattila et al. 2001) . Endothelial cell migration also requires activation of the MAPK pathway (Shono et al. 2001) . Cell migration and prolifer-ation is carried out by FGF-2 regulated expression of integrins (alphavbeta3) and cadherins (Klein et al. 1993; Sepp et al. 1994; Underwood et al. 2002) with eventual maturation of the new vessels by inducing endothelial cell production of ECM components (Gerritsen et al. 2003) . FGF-2 and VEGF/VEGFR systems maintain distinct biological roles but also work in concert to achieve angiogenesis (Presta et al. 2005) .
Angiostatin: A 38-kDa proteolytic fragment of plasminogen is a robust anti-angiogenic factor (O'Reilly et al. 1994a,b) . The cornea is a hub for angiostatin production as evident from its presence in the tear film of contact lens wearers (Sack et al. 1999) , presence of plasminogen in the corneal epithelium (Twining et al. 1999 ) and detection of angiostatin-producing MMPs (MMP-2, MMP-3, MMP-7, MMP-9 and MMP-12) . In murine models, angiostatin inhibits both bFGF-induced and injury-induced KNV (Ambati et al. 2002; Cao et al. 1999) .
Endostatin: A 20-kDa proteolytic fragment of collagen XVIII bears anti-angiogenic properties (O'Reilly et al. 1997) . It is generated by proteolytic cleavage of collagen XVIII by MMPs, cathepsin L and elastase. In the eye, collagen XVIII can be found in the cornea, retina and lens capsule (Lin et al. 2001; Ohlmann et al. 2005; Azar 2006 ). Endostatin inhibits both FGF-induced and VEGF-induced KNV (O'Reilly et al. 1997; Ferreras et al. 2000) .
The PEDF is both anti-angiogenic and neurotrophic. It is found abundantly in RPE, iris and cornea (Ortego et al. 1996; Karakousis et al. 2001) and recently has also been detected in the tear fluid of healthy indivduals (Abdiu and Van Setten 2008) . Since PEDF inhibits bFGF-induced KNV (Dawson et al. 1999) it may serve as an additional molecule sustaining the cornea's 'ocular privilege'.
Matrix metalloproteinases
MMPs are a group of zinc-binding proteolytic enzymes that engage in ECM remodelling and angiogenesis (Woessner 1994) . The cornea expresses eight out of the 24 identified MMPs including collagenase I and III (MMP-1 and MMP-13), gelatinases A and B (MMP-2 and MMP-9), stromelysin (MMP-3), matrilysin (MMP-7) and membrane type-MMP (MMP-14) (Azar et al. 1996; Maeda et al. 1998; Ye and Azar 1998; Lu et al. 1999; Ye et al. 2000) . The role of MMPs in KNV is ambiguous as the same molecule has the capacity to be both proangiogenic and antiangiogenic under different conditions (Itoh et al. 1998; O'Reilly et al. 1999) .
Over the past decade, efforts to combat KNV have taken a turn towards gene therapy and nanotechnology. Of recent interest have been the Roundabout (Robo) receptor proteins which have an established role in neuronal guidance and are expressed in murine vascular endothelial cells (Robo4) during embryogenesis (Park et al. 2003) . Robo4 is unique in that it is restricted to endothelial cells, especially at sites of angiogenesis. The soluble extracellular domain of Robo4 receptor (Robo4Fc) inhibits murine VEGF-induced and bFGF-induced endothelial cell migration (Suchting et al. 2005) . Robo4 is an attractive candidate for gene therapy in KNV as latest evidence supports its anti-angiogenic activities which have been established in vitro and in mouse models of retinal and choroidal vascular disease by inhibiting VEGF-165-induced vascular leakage and angiogenesis (Jones et al. 2008) .
Proliferative diabetic retinopathy
Diabetic retinopathy (DR) is the leading cause of irreversible blindness in Americans of working age and the third leading cause of all blindness in US (Morello 2007) . With the increasing prevalence of diabetes mellitus, DR looks set to pose a significant economic and quality of life burden among the US population (Paulus and Gariano 2009) . The earliest histological features of diabetic retinopathy include capillary basement membrane thickening, loss of pericytes and loss of endothelial cells. At advanced stages, neovascularization occurs as part of proliferative DR (PDR). The breakdown of the blood retinal barrier and the consequent vascular leakage and thickening of retina are the main events involved in the pathogenesis of PDR.
Many biochemical mechanisms have been proposed to explain the development and progression of DR. Tight control of both blood glucose levels and hypertension are essential to prevent or arrest progression of the disease. Chronic hyperglycaemia leads to oxidative injury, microthrombi formation, cell adhesion, molecule activation, leukostasis and cytokine activation. Next, ischemia leads to an overexpression of growth factors and cytokines. These factors include VEGF, insulin-like growth factor-1 (IGF-1), angiopoetin-1 and angiopoetin-2 (Ang-1/-2), stromal-derived factor-1, fibroblast growth factor-2 (FGF-2) and tumour necrosis factor (TNF). These growth factors act synergystically to mediate the steps of angiogenesis, including protease production, endothelial cell proliferation, migration and tube formation (Grant et al. 2004) . Intraocular anti-angiogenic factors include PEDF, thrombospondin (TSP), TGF-B and somatostatin whose levels are reduced in the PDR environment. Ultimately, it is the balance between pro-angiogenic and anti-angiogenic factors that determines the development and progression of PDR (Simo et al. 2006) . Because of the complex interplay among these factors, targeting a single growth factor is unlikely to result in therapeutic inhibition of angiogenesis.
Herein we examine the molecular mechanisms and genetic associations that contribute to neovascularization in the pathogenesis of PDR. nal hypoxia, a number of vasoactive factors may interact to promote pathology in a variety of cell types including the microvasculature, neurons and glia. In addition to hyperglycemia, overproduction of reactive O 2 species by mitochondria, advanced glycation end products (AGEs), hexosamines and increased polyol metabolism of glucose leads to altered signalling of pathways involving protein kinase C, nuclear factor kappa-B (NFK-B) and MAP kinase. These changes damage retinal endothelial cells, pericytes, neurons, glia and pigment epithelial cells and recruit inflammatory cells which produce vasoactive compounds, growth factors, coagulation factors and adhesion molecules that eventually leading to angiogenesis and tissue remodelling (Pelikanova 2007) .
Vascular endothelial growth factor
VEGF is universally accepted as the primary regulator of vessel patency in vascular networks throughout the body, including the retina. VEGF, a 40-kDa glycoprotein is pleiotropic and is involved in ROP, DR and AMD-the leading causes of irreversible visual loss in developed countries from infants to the elderly (Penn et al. 2008) . Elevated levels of VEGF are associated with angiogenesis in PDR (Adamis et al. 1994) .
Hyperglycemia leads to functionally and anatomically incompetent capillaries which leads to capillary nonperfusion, hypoxia and consequently induction of VEGF-A leading to angiogenesis (Crawford et al. 2009 ). VEGF induces complex formation of KDR-B3 integrin leading to phosphorylation of KDR. In mutant B3 integrin knock-in mice, VEGF-induced KDR phosphorylation was inhibited leading to incomplete formation of capillaries and in vitro inhibition of angiogenesis (Mahabeleshwar et al. 2006) .
Hypoxia resulting from hyperglycemia-induced ischemia also promotes VEGF expression. In vitro studies with RPE cells under hypoxic conditions (1% of O 2 ) show increased expression of VEGF. Hsp90i and geldanamycin inhibit hypoxia-induced angiogenic response in RPE cells (Wu et al. 2007) .
VEGF polymorphisms associated with PDR
A number of genetic polymorphisms within the VEGF gene have been associated with an increased risk of developing PDR. In Indian population, polymorphisms in the 5 UTR and promoter region of VEGF are thought to be a major genetic risk factor for DR (Suganthalakshmi et al. 2006) . The AA genotype at −2578C/A polymorphism in VEGF gene is associated with PDR, especially so in patients with diabetes for less than 15 years. While the −634C/G polymorphism in VEGF gene is not associated with PDR (Nakamura et al. 2009) , it is associated with higher risk for DR in patients with microalbuminuria (Uthra et al. 2008) . Many VEGF single nucleotide polymorphisms (SNPs) dictate the severity of PDR (Churchill et al. 2008) .
The VEGF −460C polymorphism is a positiveindependent-predictive factor for the development of proliferative diabetic retinopathy (Ray et al. 2004 ). Ray and colleagues used transfection studies to show that the VEGF −460 and VEGF +405 polymorphisms increased basal VEGF promoter activity by 71% compared with the wild-type sequence. Increased VEGF production from highexpressing haplotypes, including −460C, may promote neovascularization.
D allele I/D polymorphism in the promoter region of the VEGF gene is associated with retinopathy but not nephropathy in type 2 diabetes patients (Buraczynska et al. 2007) . Multivariate logistic regression analysis showed that the D allele of the VEGF polymorphism is an independent risk factor of diabetic retinopathy after controlling other clinical variables.
VEGF and connective tissue growth factor
Connective tissue growth factor (CTGF) acts to promote fibroblast proliferation, migration, adhesion and extracellular matrix formation, and its overproduction is proposed to play a major role in pathways that lead to fibrosis (Moussad and Brigstock 2000) . The ratio between CTGF and VEGF in the vitreous of PDR patients dictates the degree of fibrosis and angiogenesis. We know that the vitreous of PDR patients have elevated levels of both CTGF and VEGF. Raised CTGF levels are associated with VEGF and fibrosis, but only VEGF itself is responsible for NV in PDR. In vitro, CTGFinduced production of fibronectin and VEGF expression had no direct effects on vascular endothelial cells. CTGF may promote formation of proliferative membranes in PDR but not its cicatrization. It may be implicated indirectly in modulating VEGF expression but has no effects on retinal NV (Kita et al. 2007 ). Anti-VEGF therapy can temporarily tip the CTGF/VEGF ratio towards a profibrotic environment (Kuiper et al. 2008) . CTGF induces growth of hyalocytes and bovine retinal pigment epithelial cells by activation of the MAPK pathway and 3 H-thymidine incorporation.
VEGF and inflammation
There is a distinct relationship between VEGF and the prostaglandin-cyclooxygenase system. Prostaglandins that mediate inflammation also influence retinal blood flow and have been found to be pro-angiogenic. Recent evidence suggests that cyclooxygenase-2 (COX-2) modulates angiogenesis by interacting with the VEGF system. Nitric oxide (NO) is a vasodilator and is implicated in VEGF mediated vascular permeability and angiogenesis. Emerging evidence indicates that COX-2 also interacts with NO and that these two systems have reciprocal effects on each other. There is little doubt that the interactions between these three vasoactive systems are complex and require further study in the context of retinal vascular permeability, angiogenesis and neurodegeneration .
Monokines induced by IFN-y (Mig), like IL-1 and TNFalpha, and VEGF levels were raised in vitreous of DR patients implicating the synergistic role of Mig with VEGF in the pathogenesis of retinal NV in DR (Wakabayashi et al. 2008) .
Angiopoietins
Angiopoietin-1 and angiopoietin-2 interact with VEGF to promote angiogenesis in animal and in vitro models. Angiopoietin-2 levels were twice those of angiopoietin-1 in the vitreous of patients with nonPDR and clinically significant macular edema, implicating the role of Ang-2 in promoting VEGF-induced hyperpermeability that causes vascular leakage (Patel et al. 2005) . Ang-1 is thought to act as an anti-permeability agent and is a natural antagonist of Ang-2. Increased plasma levels of VEGF and Ang-2, as well as lower soluble Tie-2, were found in diabetic patients. Together with increased VEGF, elevated Ang-2 levels offer a synergistic mechanism to stimulate vasoproliferation in PDR (Watanabe et al. 2005b) . The highest VEGF and Ang-2 levels were seen among patients with preproliferative and proliferative retinopathy, but there was no relation of Tie-2 to the severity of retinopathy (Lip et al. 2004) .
Erythropoietin
Erythropoietin (Epo), a stimulator of red blood cells, is also a promoter of vascular endothelial cell proliferation and angiogenesis (Bikfalvi and Han 1994) . Both Epo and VEGF respond to hypoxia (Krantz 1991) leading to ischemia-induced angiogenesis. Epo and VEGF were both raised in the vitreous of patients with PDR and act independently of each other. Epo levels are higher than that of VEGF and its inhibition suppresses retinal NV both in vivo and in vitro. Suppression of Epo and VEGF leads to greater inhibition of retinal NV than when either is inhibited alone (Watanabe 2007) . In vitro inhibition of Epo leads to attenuation of endothelial cell proliferation in PDR (Takagi et al. 2007 ). In murine models of oxygen-induced retinopathy, inhibition of Epo led to inhibition of retinal NV in vivo and inhibition of retinal endothelial cell proliferation in vitro (Watanabe et al. 2005a) . Even though this evidence may tempt us to target Epo in the development of a retinal anti-angiogenic strategy, we must be cognizant of its neuroprotective effects on retinal cells (Becerra and Amaral 2002) and design with caution.
Anti-angiogenic factors
Given the prominent role of proangiogenic factors in the development of PDR, several antiangiogenic factors have been identified as potential therapeutic agents. Prolactin-related vasoinhibin which has an anti-angiogenic activity, is underexpressed in patients with DR (both proliferative and nonproliferative) compared to subjects without DR (0.041) (Triebel et al. 2009 ).
Certain dietary compounds (lutein, omega 3 fatty acids, eicosapentanoic acid and astaxanthin) have been thought to have antiangiogenic and anti-inflammatory effects, thus retarding CNV and DR (Ishida 2009 ) Puerarin, extracted from the Chinese herb Puerariae lobata, reduces expression of VEGF and HIF-1 in STZ-Wistar rats to reduce DR (Teng et al. 2009) .
PEDF is an antioxidant glycoprotein, which is thought to play a significant antiangiogenic and hence protective role in the development of PDR. The aqueous of patients with PDR has significantly less PEDF than that of age-matched and sex-matched normoglycemic controls. Patients with PDR have low PEDF levels in the vitreous with elevated levels in the plasma (Ogata et al. 2007) . Patients with PDR and CSME have high levels of vitreal VEGF and low levels of PEDF compared to nonproliferative DR (Patel et al. 2006; Yokoi et al. 2007) . Lower levels of PEDF and higher levels of VEGF in the vitreous may be related to the angiogenesis in DR that leads to active PDR (Ogata et al. 2002) . Animal models of DM-II as exemplified by the db/db mice also show increased levels of vitreal VEGF and low levels of PEDF at 18-20 weeks gestation consistent with early DR (Cohen et al. 2008) . Antibodies to PEDF blocked vascular proliferation suggesting that levels of PEDF may determine proliferative angiogenesis in PDR (Boehm et al. 2003) . Vitreal levels of sFlt-1 and VEGF are significantly raised with corresponding decreased levels of PEDF in PDR patients versus patients with macular hole (Matsunaga et al. 2008) . In addition, SNPs in the promoter region of PEDF, rs12150053 (TC and CC) and rs12948385 (GA and AA), are associated with DR. Increased susceptibility to DR in patients with these SNPs can be attributed to their increased interaction with the VEGF gene (Iizuka et al. 2007) .
Inflammation
Inflammation plays an important role in the development of DR by promoting the invasion of pro-angiogenic inflammatory cells. Serum levels of patients with severe NPDR showed significantly elevated levels of RANTES/CCL-5 and SDF-1 alpha. CCL5 is chemotactic for T-cells, eosinophils and basophils, and plays an active role in recruiting leucocytes into inflammatory sites. FGF-2 promotes neovascularization by inducing pro-inflammatory mediators, recruiting monocytes/macrophages leading to NV (Presta et al. 2009 ). Diabetic retinas stain positive for ICAM-1/CD54, which mediates neutrophil adhesion, and the inner retina expressed MCP-1/CCL-2 and RANTES (Meleth et al. 2005) . This indicates that in DR, a pro-inflammatory environment causes upregulation of vascular adhesion molecules that promote inflammatory cell infiltration and neovascularization.
The PDR retinal environment is characterized by upregulation of iNOS, COX-2, ICAM-1, caspase 1, VEGF, NFK-B, and increased production of NO, prostaglandin E2, IL-1beta, as well as increased permeability and leukostasis. Localized inflammation is responsible for capillary occlusion and degeneration leading to the ischemia-induced vasculogenesis, which results in PDR (Kern 2007) . Increased leukocyte ad-hesion (via ICAM1-CD18) to retinal vascular endothelium with resulting endothelial damage, breakdown of the bloodretina barrier (BRB), capillary non-perfusion and ischemia contribute to neovascularization. Inhibition of integrin alpha-4, which forms a part of VLA-4 that binds to VCAM-1, decreases TNF-alpha, VEGF, NFK-b, reduces leukocyte adhesion and vascular leakage (Iliaki et al. 2009 ).
In addition to hyperglycemia, hypertension is one of the most common co-morbid conditions in diabetic patients and exacerbates inflammatory damage to the retina. STZinduced diabetes in 4-weeks and 12-weeks old SHR and WKY rats revealed increased ED-1 + cells, ICAM-1 and VEGF in diabetic hypertensive rats implying earlier onset of retinal inflammation in diabetic retina as compared to their normotensive counterparts (Silva et al. 2007) .
Cytokines produced by inflammatory cells play a central role in the pathogenesis of PDR by increasing promoting leucocyte-mediated damage to retinal vasculature (Adamis and Berman 2008) . NADPH oxidase, produced by neutrophils, is associated with leukocyte adhesion and vascular leakage in DM and NV in OIR. NADPH oxidase is a mediator of DR possibly by reducing PPAR gamma and activating the NFK-B pathway (Tawfik et al. 2009 ). PPAR-gamma is reduced in DM, OIR and retinal inflammation, while NFK-B expression is activated in DM retina. In vitro, DPI, apocynin and SOD prevented suppression of PPAR-gamma in bovine retinal endothelial cells treated with high glucose.
In this environment, the balance is shifted in favour of MMPs and away from their inhibitors, tissue-inhibitor of matrix metalloproteinases (TIMPs). MMP-2 and MMP-9 actively degrade collagen IV, which is a major component of basement membranes, causing the ECM degradation needed for angiogenesis in DR. MMP-2 expression is much higher in patients who also have SNPs in the MMP-2 gene (Beranek et al. 2008) . Such SNPs may predispose to PDR. MMP-9 also degrades insulin and activates IL-8 thus recruiting inflammatory cells such as monocytes and neutrophils which release VEGF. MMP-9 induces inflammatory cell migration and degrades PEDF, which is an important anti-angiogenic protein in the eye (NadukKik and Hrabec 2008). Elevated levels of MMP-2 and MMP-9 contribute to the pathogenesis of PDR.
Chemokines and ECM molecules
Interleukins are primary mediators of inflammation, play an important role in DR pathogenesis and are prognostic markers of PDR disease severity. Patients with PDR have increased vitreal levels of IL-1 and TNF-alpha, which induce ICAM-1 expression (Demircan et al. 2006) . Aqueous humour levels of IL-6 and VEGF correlate with respective levels in the vitreous and their concentrations increase with severity of disease (Funatsu et al. 2005) . Early stage DR is associated with elevated levels of serum CD105 (which is thought to be involved in vascular remodelling) and vitreal VEGF which then decrease through the course of disease progression to severe PDR (Malik et al. 2005) . IL-6 (T-cell activation), IL-8 (neutrophil chemotaxis), MCP-1 and VEGF levels are also significantly higher in the vitreous of patients with PDR (Murugeswari et al. 2008 ). IL-18, which induces macrophage activation via interferon-gamma, is raised in the sera of patients with DM2 and background DR (Skopinski et al. 2005) . Thus, interleukins play an important role in mediating the inflammation and neovascularization in the development of PDR.
Growth factors and enzymes associated with DR

Insulin-like growth factor
Growth factors trigger the molecular events that induce retinal neovascularization. IGF-I is produced locally in the human eye by a variety of cells including RPE cells, retinal capillary pericytes, endothelial cells, Mueller cells and ganglion cells. Normoglycemic/normoinsulinemic transgenic mice overexpressing IGF-1 in the retina developed most alterations seen in human diabetic eye disease (Ruberte et al. 2004 ). The two month-old transgenic mice showed loss of pericytes and thickening of basement membrane of retinal capillaries. In six months and older mice, venule dilatation, intraretinal microvascular abnormalities, and neovascularization of the retina and vitreous cavity were observed (Ruberte et al. 2004) . Neovascularization was consistent with increased IGF-1 induced VEGF-expression in retinal glial cells (Ruberte et al. 2004) .
In cultured human RPE cells, IGF-1 is thought to exert its effect by inducing a dose-dependent increase in IGF-1R phosphorylation and in VEGF mRNA levels. IGF-I also stimulates VEGF promoter activity in vitro, mainly via HIF-1alpha, and secondarily via NFK-B and AP-1 (Poulaki et al. 2004) . In a south Indian cohort, a CA 18-repeat genotype in the promoter of IGF-1 is implicated in susceptibility to PDR and associated with clinical severity (Uthra et al. 2007) .
Further evidence for the role of IGF-1 in PDR comes from the use of IGF-1 inhibitors. Somatostatin and octreotide, a somatostatin analogue, inhibited IGF-1 receptor (IGF-1R) phosphorylation and decreased VEGF production (Sall et al. 2004) . Systemic inhibition of IGF-I signalling in a relevant animal model with a receptor-neutralizing antibody, or with inhibitors of PI-3 kinase (PI-3K), c-Jun kinase (JNK), or Akt, suppressed downstream signalling pathways, VEGF expression, ICAM-1 levels, leukostasis, and BRB breakdown. Intravitreous administration of IGF-I increased retinal Akt, JNK, HIF-1alpha, NFK-B, AP-1 activity, and VEGF levels. Therefore, understanding of the molecular pathways by which IGF-1 plays a role in PDR may lead to the development of specific therapies based on inhibition of either IGF-1 or its downstream actors (Poulaki et al. 2004 ).
Aldose reductase (AR) is responsible for the early events in the pathogenesis of diabetic retinopathy, including BRB breakdown, loss of pericytes, neuro-retinal apoptosis, glial reactivation, and neovascularization. In db/db mice with a null mutation for AR, retinal blood vessels were found to leak IgG suggesting that AR may contribute to BRB breakdown. AR deficiency also prevented diabetes-induced reduction of platelet/endothelial cell adhesion molecule-1 expression and increased expression of VEGF, which may have contributed to blood-retinal barrier breakdown. In addition, long-term diabetes-induced neuro-retinal stress and apoptosis and proliferation of blood vessels were less prominent in AR-/-db/db mice (Cheung et al. 2005) .
The renin-angiotensin system (RAS)
Both human and rat retinas have angiotensin receptor (ATR) type-1 and ATR-2. In both human and rat models of DR and hypoxia-induced retinal angiogenesis the RAS is upregulated leading to the production of VEGF, PDGF and CTGF leading to microvascular complications, angiogenesis, cell proliferation and fibrosis (Wilkinson-Berka 2006) .
The RAS exerts its effects by the generation of a family of bioactive angiotensin peptides among which angiotensin II (ANG II) and the ATR-1 and ATR-2 receptors are most well characterized . Emerging evidence suggests that an ocular RAS is activated in DR and may contribute to progressive alterations to retinal cells such as pericytes, endothelial cells, neurons and glia. In the kallikrein-kinin system (KKS), bradykinin (BK) and kallidin and their carboxypeptidase metabolites, des-Arg(9)-BK and des-Arg(10)-kallidin are the effector peptides exerting their actions via BK type 1 (BK-B1) and BK type 2 (BK-B2) receptors. Both RAS and KKS damage the retinal vasculature and glia in DR via production of VEGF and CTGF .
The RAS is also implicated in progression of DR via Ang II. Ang II induces VEGF, which leads to the loss of tight junction proteins causing a breach in the integrity of the BRB. Angiotensin receptor blockers that block Ang II receptors reduce VEGF production by retinal endothelial cells and promote the recovery of tight junction proteins thus preventing progression of DR in its early stages (Kim et al. 2009) .
Important cross-talk exists between the RAS system, advanced glycation end products (AGEs) and their receptors (RAGE). AGEs act via RAGE to cause diabetic microvascular complications leading to PDR (Yamagishi et al. 2005) . CCN1/Cyr61 is a member of the cysteine-rich 61/connective tissue growth factor/nephroblastoma overexpressed (CCN) family of genes. It is a downstream effector of AGE in the diabetic retina and may work synergistically with VEGF to cause ocular angiogenesis and PDR in models of oxygen induced retinopathy (OIR) in mice and streptozotocin (STZ)-induced DM in rats. Levels of both CCN1 mRNA and protein are raised in vitreous of STZ rats and PDR patients (non-diabetics) (Hughes et al. 2007 ). AGEs-RAGEinduced VEGF expression is thought to lead to neovascularization in PDR. Olmesartan, an angiotensin II type-1 receptor blocker, inhibited angiogenesis by inhibiting AGEinduced NFK-b promoter activity and consequently NFKb-mediated RAGE expression (Yamagishi et al. 2008) . AGEs also induce injury of retinal pericytes, which are protected by PEDF expression. Thus, a decrease in PEDF expression can amplify the effect of AGEs on RPE integrity leading to PDR (Chmielewska et al. 2008) .
Retinopathy of prematurity
Retinopathy of prematurity (ROP), formerly known as retrolental fibroplasia, was first described in 1942 and is one of the leading causes of blindness in children (Terry 1942 ). While we have ablative treatments today such as cryotherapy and lasers, it is important to understand the molecular pathogenesis as it may help us discover preventive methods. The main pathology in ROP is abnormal angiogenesis. In the normal-term baby, there is a vasculogenesis phase in which the blood vessels sprout off the hyaloid and create the vasculature reaching toward the retina until week 21 of gestation (Hughes et al. 2000) . The second phase termed the angiogenic phase, overlaps with the first, beginning at 17 weeks and is driven by physiological hypoxia. The existing vasculature remodels and branches to create more vessels to meet the higher oxygen demands of the growing structures (Ashton et al. 1954; Hughes et al. 2000) . ROP occurs in premature infants with disruption of this angiogenic phase. Premature neonates are exposed to higher oxygen levels in the early stages of retinal vascular development, eliminating physiological hypoxia, thus downregulating angiogenic factors that are necessary for the growth of the vasculature. This results in a vaso-obliterative phase and is seen in infants born prematurely at 30-32 weeks (Ashton et al. 1954; Madan and Penn 2003; Chen and Smith 2007) . Since angiogenesis is interrupted, the retina becomes hypoxic, inducing the proliferation of new vessels between the vascularized and avascular retina; this is termed the vaso-proliferative phase of ROP (Ashton et al. 1954; Smith 2008 ). The pathological vasculature can cause fibrous scarring in the retina, vitreous and lens causing traction which can lead to retinal detachment and blindness (Chen and Smith 2007) .
Oxygen and hypoxia inducible factor
As described earlier, after vasculogenesis, angiogenesis in the normal retina in utero is driven by hypoxia. This high oxygen demand is mostly due to rod development (Arden et al. 2005) . The main pathology in ROP is that the baby is prematurely exposed to abnormal oxygen levels, which govern development. Hypoxia-inducible factor-1alpha (HIF), is a transcription factor that upregulates angiogenic factors under hypoxia. When the oxygen tension is normal, HIF is rapidly oxidized by hydroxylase enzymes, but when cells become hypoxic, HIF escapes degradation and accumulates, triggering the activation of a number of genes, like VEGF and EPO (Arjamaa and Nikinmaa 2006) . This system is tightly regulated; even a mild change in regimen of the ROP induction model to 45 to 12.5% O 2 from the 40 to 15% O 2 model yielded 78% increase in release of VEGF. The release of VEGF is highly sensitive to the slightest change in oxygen levels and the amount of change in oxygen level (Werdich et al. 2004 ). Inhibiting prolyl hydroxylase, an inhibitor of HIF has been shown to reduce ROP in mice. This may be a possible therapeutic intervention by chemically stabilizing HIF and maintaining the conditions of 'physiological hypoxia' (Sears et al. 2008) . One study showed that inducible nitric oxide (iNOS) may be the one mediating HIF activation via PI3K/Akt signalling pathway and may be an other avenue of intervention (He et al. 2007 ).
VEGF
VEGF is an important regulator of angiogenesis and plays a crucial role in both phases. Unlike other factors it is not constitutively produced but temporally and spatially induced during vasculogenesis (Murata et al. 1996) . Normally during angiogenesis, VEGF levels should rise due to the elevation in HIF (Shweiki et al. 1992; Penn et al. 2008) . However in phase 1 of ROP, these levels decrease within 6 h under normoxic or hyperoxic conditions (Pierce et al. 1995 (Pierce et al. , 1996 Shweiki et al. 1992) . VEGF is strictly under the control of oxygen and HIF; between 17% and 45% oxygen, the extent of vasculogenic cell division is inversely proportional to the level of oxygen (Chan-Ling et al. 1995) . In ROP, VEGF is the 'master switch', its low levels decrease angiogenic signalling and allow the retraction of blood vessels by apoptosis of endothelial cells. Exogenous administration of VEGF and VEGFR-1 specific ligand can counteract this effect of hyperoxia in the first phase of ROP (Alon et al. 1995; Pierce et al. 1996; Shih et al. 2003; .
In stage two of ROP as the retina becomes hypoxic, VEGF levels rise within 6-12 h (Pierce et al. 1995) . VEGF is produced by neighbouring astrocytes and affect endothelial cells in a paracrine fashion. These endothelial cells then exhibit high affinity receptors Flk-1 (also known as VEGFR2), which are specific for proliferative neovasculature (McLeod et al. 2002) .
VEGF is a major target for therapeutic intervention in ROP. Thus far, VEGF inhibition via monoclonal antibodies and hyperoxia, and factors such as thrombospondin-1 and PDGF, have been used to decrease the proliferative angiogenesis in phase 2 of ROP (Pierce et al. 1996; Suzuma et al. 1999; . Several other inhibitors such as alpha versus beta integrins, alpha-defensins, nonpeptide antagonists and PEDF decrease VEGF mediated migration, EC permeability and proliferation and may have a potential therapeutic application (Hutchings et al. 2002; Economopoulou et al. 2005; Wilkinson-Berka et al. 2006) . Eph receptor tyrosine kinase blockade has also become an area of interest as it inhibits new vessel formation without interrupting existing structure (Chen et al. 2006) . Angiotensin 2 receptor blockade has also been explored as recent studies have shown the involvement of the RAS system in angiogenesis (Sarlos et al. 2003) . More recently, gene therapy such as anti-VEGF SiRNA has been effective in reducing retinal neovascularisation (Jiang et al. 2009 ).
Erythropoietin
Erythropoietin (EPO) is a hormone that is initially secreted in the foetal liver and later by the kidney as an adult. Though EPO is known for its hematopoietic qualities, recently it has gained interest in its influence on angiogenesis after success in stroke therapy. Studies have shown that it effects endothelial cells and angiogenesis as much as VEGF but through an independent mechanism (Jaquet et al. 2002; Sato et al. 2009 ). EPO is part of normal eye development; expression of the protein and receptor can be found in the retina and its vasculature . While HIF levels stay the same during embryonic development, EPO serum levels rise about seven fold from 15-24 weeks of gestation. A recent study measuring mRNA and protein concentrations have shown that EPO levels are six times higher in the vitreous than in the plasma during gestation weeks 15-17. This difference decreases to two-fold by gestational age 21-24 weeks (Patel and Chan 2008) . Like VEGF, EPO is also regulated by HIF or HIF-1alpha like factor (HLF), and its levels are reduced under hyperoxic conditions. In HLF deficient mice under OIR (oxygen induced retinopathy) showed no ROP and decreased levels of EPO .
Timing is critical in the role of EPO. Studies have shown that EPO levels are low during the vaso-obliterative phase. Administration of exogenous EPO during this phase inhibited retraction and stabilization of vessels due to proangiogenic bone marrow derived progenitor cells. It also has neuroprotective qualities such as resistance of hypoxia induced neuronal apoptosis, reduction of reactive oxidative stress, and inhibition of inflammatory chemokines Wang et al. 2009 ).
However, in the vasoproliferative phase of ROP, exogenous EPO administration can be harmful. Retrospective studies have shown the incidence of retinopathy of prematurity increase when EPO was used to reduce blood transfusions in premature children (Brown et al. 2006; Suk et al. 2008) . ROP occurs if given during phase two or around eight days after birth by augmenting pathological angiogenesis (Schneider et al. 2008) . So far, interference technology has been successful in preliminary studies showing anti-EPO siRNA significantly reducing ROP in mice ).
IGF-1
IGF-1 is a maternally derived factor that is provided by the placenta and amniotic fluid (Langford et al. 1998) . In addition to post-menstrual age at birth and low birth weight, studies have shown that low IGF serum levels can be used as a screening factor for predicting ROP (Hellstrom et al. 2003; Villegas-Becerril et al. 2006) . Further interrogation has revealed that these factors have a direct influence on angiogenesis. In a mouse model, GH inhibition decreased ischemia induced neovascularization which was recovered by exogenous administration of IGF-1 (Smith et al. 1997) .
While VEGF is increased by HIF under hypoxia, IGF-1 is required for the angiogenesis to take place. In vitro studies have shown that low levels of IGF-I prevent VEGF-induced activation of protein kinase B (Akt), a kinase critical for endothelial cell survival (Hellstrom et al. 2001) It is thought that if IGF levels are insufficient at birth, the retina stays avascular and VEGF levels begin to accumulate until IGF levels reach a threshold, at which point the vasoproliferative phase begins. IGF-1 receptor regulation of VEGF action is mediated through control of VEGF activation of p44/42 mitogen-activated protein kinase (Smith et al. 1999) . Increasing levels of IGF or exogenous administration of IGF to maintain high levels in a premature infant may be a potential avenue of therapy (Smith 2005; Vanhaesebrouck et al. 2009 ). Somatostatin, an inhibitor of growth hormone plays a role in regulation as its receptors (sst2) have also been identified on the RPE. Physiological amounts of somatostatin and its analogue octreotide inhibit VEGF and IGF-mediated neovascularization and may also be used as a potential therapy (Sall et al. 2004 ).
Omega-3 PUFAs
Like IGF, Omega-3 PUFAs (omega 3 polyunsaturated fatty acids) are maternally derived and given to the foetus in the third trimester, and this is deficient in premature children (Connor et al. 2007 ). Omega-3 PUFAs have shown to decrease avascular areas and increase vessel regrowth after injury. In addition, neuroprotectinD1, resolvinD1 and resolvinE1 are all derived from omega-3 PUFAs. These bioactive metabolites are neuroprotective in addition to reducing TNF alpha mediated angiogenesis. Neuroprotectin D1 also aids in brain cell survival and repair involving neurotrophic, anti-apoptotic and anti-inflammatory signalling. Lack of these properties may contribute to the susceptibility of ROP (Mukherjee et al. 2007; Lukiw and Bazan 2008) .
Exudative age related macular degeneration
Age related macular degeneration (ARMD) is the major reason for blindness in the elderly population. It is a multifactorial disease that progresses from damage of the retinal pigment epithelium and Bruchs membrane, leading to the phenotypes of geographic atrophy and neovascularization. The latter, exudative type involves abnormal angiogenesis causing choroidal neovascularization under the retinal pigment epithelium which can ultimately lead to blindness. There are a number of factors we will discuss in this next section that mediate angiogenesis and help us gain a better understanding of the mechanisms and pathogenesis of wet ARMD.
VEGF
Originally known as vascular permeability factor and discovered in tumour cells, VEGF has become the main factor that mediates angiogenesis in ARMD. VEGF, a relative of the PDGF family is a secreted protein mitogen (Keck et al. 1989; Leung et al. 1989) . It acts by promoting endothelial cell proliferation and survival, ocular inflammation and increasing permeability by creating fenestrations in postcapillary and muscular venules and capillaries (Roberts and Palade 1995) . In addition, it is the major regulator of a number of downstream factors. Despite its pathological role in ARMD, VEGF is a protein that is necessary for early life and normal eye development. Deficiency in the VEGF gene causes hypoplastic vasculature and death in utero (Carmeliet et al. 1996) .
VEGF is constitutively produced, but in ARMD, its levels are elevated due to damage, ischemia and hypoxia. VEGF is produced at a much higher concentration basally near the VEGF receptors on the choriocapillaris under hypoxic conditions (Blaauwgeers et al. 1999) .
While VEGF is the main regulator in ARMD, increased VEGF alone is not enough to cause subretinal neovascularization. A transgenic model of increased VEGF production by RPE and choroid showed that vasculature is increased but only within the choroid and none had invaded Bruch's membrane. Additional environmental insults and the balance of the angiogenic versus anti-angiogenic factors determine whether choroidal neovascularization will be present (Schwesinger et al. 2001) .
Pigment epithelium derived factor
PEDF, initially known as a neurotrophic factor, has antiangiogenic properties that maintain the eye free of vascularization by reducing VEGF induced chemotactic endothelial cell migration and proliferation via apoptosis (Mori et al. 2001) . While it is present in many of the ocular tissues constitutively, it is highly expressed in the RPE covering CNV at much higher levels when neovascularization first occurs (Ogata et al. 2002) .
Most studies have demonstrated PEDFs inverse relationship to CNV, its downregulation the likely cause of CNV (Shi et al. 2004) . A cadaver eye study measuring VEGF and PEDF showed significant decreased in PEDF in choroidal tissues with those with ARMD as compared to age matched normal (Bhutto et al. 2006) . Aqueous humour of ARMD patients with active CNV exhibited angiogenic properties . PEDF levels measured in CNV/AMD vitreous was on average 2.8 ng/µL +/− 1.3 ng/µL compared to 16.4 ng/µL +/− 7.1 ng/µL in normal age matched vitreous. In addition, the vitreous of normal adults had no endothelial chemotactic properties and even resisted VEGFinduced migration (Holekamp et al. 2002) . In the retina, the VEGF/PEDF ratio is 10:1 with neovascularization, and increases as vascularization progresses. This has been shown by measuring mRNA concentrations of the factors in the ARMD rat model as compared to age-matched controls (Gao et al. 2001; Renno et al. 2002) . In late stages of ARMD, PEDF is directly related to the oxygen levels in the eye and is reduced in ischemic eyes or those under oxidative stress. (Dawson et al. 1999; OhnoMatsui et al. 2001) .
VEGF and PEDF seem to regulate each other via feedback mechanisms in a tightly controlled manner. An examination of cultured endothelial cells (CEC) displayed how PEDF had no impact on normal cells while it inhibited the migratory effects of VEGF-induced endothelial cells . PEDF is upregulated by VEGF through VEGFR-1 in human RPE. It is mediated by two different pathways: intramembrane proteolysis of VEGF-1 and inhibition of VEGFR-1 phosphorylation by VEGF (OhnoMatsui et al. 2003) .
PEDF decreases CNV, but only if administered exogenously in high amounts during initial vascularisation (OhnoMatsui et al. 2001) . Thus far, high doses of PEDF have been successful via adeno association vector in mice (Mori et al. 2002) and in pigs (Saishin et al. 2005) . However this was contradicted when the various doses of administered PEDF were taken into account. While a low dose was inhibitory, high dose of PEDF augmented neovascularization with VEGF (Apte et al. 2004 ). Intriguingly, a PEDF knockout mouse model had an entirely normal ocular phenotype (Yoncopoulos G. and Wiegand S. PEDF-knockout-mice have a normal ocular phenotype. A poster presentation at Association for Research in Vision Science and Opthalmology, Fort Louder date, May 2007).
There is contradictory evidence of the role of PEDF. We now know that it initially increases when neovascularization occurs. This is likely a negative feedback mechanism to the increased VEGF. Overall, it is the decrease in PEDF that probably makes one susceptible to ARMD. While exogenous PEDF had been shown to be successful in what..?, It seems that timing and dosage is crucial and it may turn out to be detrimental if used incorrectly. More recently, the role of genetics have also been explored in ARMD, and a recent study implicates the T allele of Met72Thr (T/C) of PEDF gene exon 3 to be linked with wet ARMD .
Fibroblastic growth factor
Similar to VEGF, fibroblastic growth factor (FGF) plays a crucial role in the development of the eye. Studies with mice deficient in FGF receptor 1 and FGF inhibition show that the choroid is thinned and the RPE and photoreceptor integrity is compromised in hemizygous mice. In homozygous deficient mice for FGF, eye growth is interrupted and there is severe degeneration (Rousseau et al. 2000) . FGF is responsible for development of the eyes vascular plexus, regression of the hyaloid plexus and the induction of choroidal terminal branching during embryogenesis. VEGF(165) and FGF2 play a synergistic role, both significantly increase human macular endothelial cell proliferation and sprout formation (Browning et al. 2008) .
Analysis of eyes with CNV versus normal ones via immunohistochemistry has shown a high presence of acidic fibroblastic growth factor (aFGF) and basic fibroblastic growth factor bFGF the latter being more common (Amin et al. 1994) . The deeper choriocapillaris within the stroma exhibits aFGF wheareas the bFGF is the more common type in angiogenesis. Infusion of bFGF growth factor into mini pigs has demonstrated that bFGF has direct effect of choroidal neovascularization (Soubrane et al. 1994) . Under normal conditions FGF-1 receptor mRNA is seen in the ganglion cells and the inner nuclear layer. However, during CNV, FGF production also appeared in the retinal pigment epithelial cells, in melanocytes of the choroid and in the choroid endothelial cells (Matsushima et al. 1996) . Studies have also shown a role for FGF5 in ARMD, expressed in blood vessels and the surrounding extracellular matrix of the choroid (Kitaoka et al. 1997) . Beta-FGF works via two pathways; via a calcium independent FGFR1 through PI 3-K, P70(S6K) and Akt to increased VEGF A from the RPE and a calcium dependant FGFR2 which is cascade of MEK1, ERK1/2 and P90(RSK). The inhibition of both ERK1/2 and PI 3-K activities suppresses bFGF-induced choroidal endothelial cells proliferation (Zubilewicz et al. 2001; Rosenthal et al. 2005) .
In addition to FGF, other growth factors such as connective tissue growth factor (CTGF) and transforming growth factor (TGF) are elevated and colocalized in the RPE of retinas with CNV. These two factors, stimulate fibroblasts to produce VEGF along with extracellular matrix and promote angiogenesis (Nagineni et al. 2003; Watanabe et al. 2005c) .
Angiopoietins
Like VEGF, angiopoietins are growth factors that are specific to endothelium. Angiopoietin-1 (Ang1) is a ligand for the Tie-2 receptor and an angiogenic factor that mediates communication between the endothelium and the ECM molecules. These molecules also affect late embyrogenesis along with FGF; overexpression of Ang1 allows higher branched vasculature (Suri et al. 1996 (Suri et al. , 1998 . Angiopioetin 2 (Ang2), discovered later, is a natural antagonist of Ang1 and mediates inhibition of angiogenenesis during embryogenenesis and in vivo. Ang2 is found in areas undergoing vascular remodelling and destabilizes existing blood vessels (Witzenbichler et al. 1998) . Interestingly Ang2 only causes CNV under the influence of VEGF; in the absence of VEGF, Ang2 causes regression of vessels (Peters et al. 1998) . VEGF increases endothelial cell proliferation of thin vessels that are weak and leaky. Working alone, Ang1 stabilizes ves-sels and counteracts their vascular permeability (Nambu et al. 2004) . Together, these factors have an additive effect producing abundant stable vessels during neovascularization (Nambu et al. 2005) . While Ang1 is technically angiogenic, in ARMD it appears to be protective rather than pathological allowing the reduction of microvascular leakage. Ang1 has also been found to inhibit the proinflammatory qualities of VEGF such as the upregulation of ECM molecules I-CAM, V-CAM and E-selectin to induce leukocytosis (Kim et al. 2001) .
Several studies showed that Tie-2 signalling decreased choroidal neovascularization by adenovirus-mediated gene delivery of extracellular domain of the Tie-2 receptor (Hangai et al. 2001) and inhibitory molecules of Tie-2 receptors. This may be a new avenue of therapy via angiopoietin and the Tie-2 axis ).
Nitric oxide
Through many studies, we have long known that NO is mediator of angiogenesis by way of VEGF (Papapetropoulos et al. 1997) . Studies have demonstrated this by inhibiting NOS and measuring the amount of NO that was produced (Papapetropoulos et al. 1997; Uhlmann et al. 2001) . Interestingly, timing and duration of exposure determines the type of NOS produced; long term exposure of VEGF stimulates endogenous nitric oxide synthase (eNOS) while short term exposure promotes NO release through activationg of tyrosine and PI-3K kinases. The latter inducible form (iNOS) is the pathological NO mediated by cytokines in ARMD (Hattenbach et al. 2002) . Flow cytometry studies show when iNOS is upregulated there is an increase in alpha versus beta(3) integrin expression on endothelial cells and macrophages indicating increased migration and adhesion (Lee et al. 2000; She et al. 2007) .
While iNOS may be responsible for choroidal neovascularization in ARMD, it plays a different role in oxygeninduced ischemic retinopathy. In a comparison between iNOS deficient mice and eNOS deficient mice, VEGF stimulation significantly increased permeability in both wild type and iNOS(-/-) mice but not in eNOS(-/-) mice, suggesting that eNOS plays a predominant role in hypoxia-induced angiogenesis and vascular permeability (Fukumura et al. 2001) . In the latter case, deficiency of eNOS was responsible for retinal neovascularization and iNOS was actually inhibitory .
More recent studies looking into the relationship between fatty acids and inflammation have shown that certain fats such as oleic acid, linoleic acid and linolenic acid increased the expression of iNOS and COX-2 genes and the production of prostaglandin E2 in the RPE. Linoleic acid also induces NF-kappaB transcriptional activation which promotes inflammatory pathogenesis of ARMD. On the other hand, longer unsaturated fatty acids such as Lutein are protective and block NF-KappaB activation and reduce inflammatory factors in dose-dependent manner (Fang et al. 2009 ).
ECM molecules
Studying the basal lamina and linear deposits (BLD) can provide valuable insights about the key players in the pathogenesis of ARMD. Recent study of BLD in CNV eyes demonstrated VEGF, vitronectin, MMP-2, MMP-7, MMP-9, TIMP-3 and complement C3b and C5-9 complexes (Lommatzsch et al. 2008) .
I-CAMs are adhesion molecules that promote VEGFs chemotactic ability. Its inhibition prevents permeability and leukostasis (Miyamoto et al. 2000) . Studies of ICAM-1 and leukocyte adhesion molecule CD 18 deficient mice show significantly less CNV than wild-type mice (Sakurai et al. 2003b) .
MMPs are a family of zinc dependant endonucleases that are involved in degradation of the extracellular matrix. MMP-1, MMP-2, MMP-3, MMP-7 and MMP-9 have been implicated in its relationship to wet ARMD. MMP-1 and MMP-3 are found only in Bruchs membrane where MMP-2 and MMP-9 were found in the choroid. Production of MMP-2 and MMP-9 by the RPE increases when stimulated by VEGF, fibronectin and TNF-alpha (Hoffmann et al. 2006) . This suggests that some MMPs may be selective and can be part of the pathological breakdown and remodelling of the matrix during neovascularization in ARMD (Friedlander et al. 1995; Guo et al. 1999; Kadonosono et al. 1999) . However, in experimentally induced CNV, only MMP-2 has been shown to be associated with ARMD. MMP-2 increases in macrophages and the RPE invading the choroid (Kvanta et al. 2000) . It increases from day three and peaks at day five after the initiation of CNV (Berglin et al. 2003) . Compared to age-matched control eyes, the amount of MMP-2s double in the RPE of ARMD patients (Plantner et al. 1998 ). In addition CNV was significantly reduced in genetically engineered MMP-2 deficient mice (Berglin et al. 2003 ).
Sorsby's fundus dystrophy is an inherited form of blindness which has extensive choroidal neovascularization due to a mutation in TIMP-3; leading to a premature onset of an ARMD-like phenotype (Anand- Apte et al. 1997) . TIMPs are also a group of zinc-binding endopeptidases that counteract the actions of MMPs. TIMP-3 has been localized to to the q12.1-q 13.2 region of human chromosome 22 (Apte et al. 1994 ) TIMP-3 inhibits chemotaxis of vascular endothelial cells toward VEGF and bFGF, inhibits collagen gel invasion and capillary morphogenesis in vitro, and inhibits bFGFinduced angiogenesis (Anand- Apte et al. 1997) . In ARMD eyes, TIMP-3 distribution in Bruch's membrane was abundant in areas of continuous soft drusen but absent in areas below RPE atrophy (Kamei and Hollyfield 1999) .
Studies have also focussed on the role of integrins, specifically alpha versus beta 3 and alpha versus beta 5 and their role in ocular angiogenesis. Only alpha versus beta 3 was observed on blood vessels in ocular tissues with active neovascularization from patients with ARMD whereas both were presented in other disease states such as DR. This in-dicates that certain integrins are specific to certain disease states (Friedlander et al. 1996) . A number of studies have shown that antagonists of integrins reduce CNV in ARMD (Honda et al. 2009 ). There is new evidence pointing to the involvement of ADAMs, proteins that have a disintegrin in addition to a metalloproteinase domain. They are in amplification loops with VEGF and further increase CNV. This is a new area of exploration for intervention. (Xie et al. 2008) .
Inflammation
While it was described about two decades ago early in ARMD research, the role of inflammatory cells such as macrophages, dendritic cells and microglia and complement are once again being explored in the recent years (Penfold et al. 1987) . The RPE produces a cytokine, MCP-1, monocyte chemotatic protein which recuits macrophages. Macrophages produce tissue factor, which in turn produce fibrin for infrastructure. These macrophages produce more VEGF along with the RPE (Grossniklaus et al. 2002) . We see that inflammatory cells play a crucial role in ARMD as neutropenic mice show significantly less CNV in murine models. Neutrophils also contribute as they play an early role peaking at day three and produce other angiogenic factors in addition to VEGF (Zhou et al. 2005) . Immature dendritic cells also play a role; they produce VEGFR-2 proliferate and migrate to areas of neovascularization from day 2-4 of CNV (Nakai et al. 2008) .
In MCP-1 (ccl-1/ccr-2) knockout mice, macrophages and CNV were reduced, and the macrophages produced mRNA for VEGF, b-FBF, TNF-alpha and inflammatory molecules such as CD40, B7-1 and B7-2 (Tsutsumi et al. 2003) , It seems that generalized depletion of macrophage activity decreases CNV (Sakurai et al. 2003a) . However, other studies have shown contradictory evidence. In another MCP-1(ccl-1/ccr-2) deficient mouse model, there was a higher accumulation of complement immune complexes, drusen and lipofuscin. Macrophage recruitment by RPE may actually aid in decreasing the accumulation of material between the RPE and choroid (Ambati et al. 2003) .
Microglia are also activated in response to rodphotoreceptor death and are involved in phagocytosing the injured and dead cells. In this process they may also cause nearby cone death. Any dysfunction in phagocytosis by microglia can lead to accumulation of cellular debris and activation of further inflammatory process leading to CNV (Gupta et al. 2003) An association between ARMD and CXC3R1, a chemokine produced by microglia cells (MC), has also been observed (Combadiere et al. 2007) . Lower expression of, mutation of, or a reduction in CX3CR1-induced cellular activities may contribute to ARMD development due to the accumulation of MC and debris in the subretinal layer (Tuo et al. 2004; Combadiere et al. 2007) . A study of an animal model deficient in both MCP-1 and CX3CR1 revealed severe progression to ARMD. Fifteen per cent of these mice had CNV and all showed increase in cellular debris, A2E, misfolded endoplasmic reticulum and chaperone proteins that accummulated subretinally ).
Newer models of ARMD are moving towards the comparison of ARMD to cardiovascular disease. The E4 allele of apolipoprotein E has has been shown to be protective for ARMD, whereas the E2 allele has shown elevated risk. Apolipoprotein E is involved in the metabolism of cholesterol and lipid transport, thus ARMD has been compared to an atherosclerotic pathogenesis. ApoE112R decreases ARMD by suppressing VEGF and CCl-2 expression in the RPE (Bojanowski et al. 2006) . Similar to atherosclerosis, a study with ARED's participants showed C-reactive protein was high in those with ARMD, showing that inflammation plays a role in both diseases (Seddon et al. 2004 ).
Complement
A constant low level of complement activation in the eye serves as a primary defence mechanism against pathogens and is tightly regulated by complement regulatory proteins (Bora et al. 2008) . Recent studies suggest that dysregulation of the system may mediate ARMD pathogensis (Patel and Chan 2008) . Components of all complement structures such as C5b-C9 and the MAC complex have been isolated in drusen of ARMD eyes (Mullins et al. 2000; Nozaki et al. 2006 ). It appears that it is the alternate pathway that is activated; in animal models inhibition of C4 and C1q had no effect in reducing CNV (Bora et al. 2006) . ARMD has been linked genetically and pathophysiologically with complement regulators and accessory molecules. For example, a knockout model of CD 59, a complement regulator, increased CNV and these effects were reduced when administered exogenous CD59 (Bora et al. 2007 ). There are several genetic variations of complement regulators that make one susceptible to ARMD. Chromosomal abnormalities that have been implicated thus far are 1q31-2, 6q21 and 10q26 (Gold et al. 2006; Swaroop et al. 2007) .
CFH, a negative regulator of the complement system and c-reactive protein (CRP) (Prosser et al. 2007; Yates et al. 2007 ) can be found in several ocular tissues such as the cornea, retina, choroid and RPE. A tyrosine-to-histidine change in position Y402 in the 1q32 region of CFH gene is associated with increased ARMD. This change reduced affinity of binding capactiy to glycosaminoglycans (GAG) and CRP, and dysregulation of the alternative pathyway. CFH deficient mice have C3 deposition and disorganized photoreceptors and even display signs of higher oxidative damage (Klein et al. 2005) . The possession of at least one histidine at amino acid 402 increases the risk of ARMD by 2.7. Some have insisted that it accounts for 50% correlation with ARMD (Thakkinstian et al. 2006; Kleinman et al. 2008) .
Within chromosome 6q21 are complement factor B and complement component 2 that are located 500 bp apart. These are complement activators located in MHC III region. Variants of BF, R32QBF/a and L9HBF and CC2; E318D in intron 10 of C2 are all associated with reduced ARMD, predicting clinical outcome in 74% of those affected. The protective effect is likely due to decreased enzymatic activity in complement response. Though the direct mechanism is still unknown, animals models with knockout BF have shown reduced levels of CNV (Gold et al. 2006) . However, later studies have not shown similar results. While they show an association with ARMD, it is not as high as that of CFH or HtrA1 and the researchers have attributed the association to other unidentified SNPs located in that region and due to their strong linkage disequilibrium (Spencer et al. 2007; McKay et al. 2009) .
Within chromosome 10q26 is HtrA1, a gene for a heat shock serine protease that is upregulated during cellular stress and inhibits the Tgf-beta family of proteins by blocking receptor activation (Oka et al. 2004) . HtrD1 is constitutively expressed in ocular tissues for normal eye development but is highly expressed in those with ARMD, wet>dry (Oka et al. 2004; Chan et al. 2007) . It is thought that HtrA1 induces apoptosis and degradation of the ECM proteins. An SNP, rs11200638, in the promoter of HtrA1 has a high association with wet ARMD and shows increased levels of HtrA1 mRNA and protein in affected individuals (Chan et al. 2007) . Recently, another polymorphism 512G>A, has also been shown to be associated with ARMD (Tang et al. 2009 ). Two other alleles, PLEKHA1 and LOC387715 next to HtrA1 are strongly associated with ARMD susceptibility (Swaroop et al. 2007; Ross et al. 2007) . SNP rs1045216 in PLEKHA is associated with increased CNV as is rs10490924 in the hypothetical LOC387715/ARMS2 gene (Conley et al. 2006) . LOC387715/ARMS2 and PLEKHA1 maybe involved in intracellular remodelling and lymphocytic activation (Swaroop et al. 2007; Ross et al. 2007) .
Variations in C3 at chromosome 19p13 have been associated with ARMD. C3 is a main component of the complement cascade and its cleavage products have been found in drusen . Its deficiency reduces angiogenic factors such as VEGF, TGF-B2 and B-FGF in the eye Bora et al. 2006) . Studies have shown that a certain variation in SNPs in this complement factor and have been associated with ARMD, particularly a variation of one amino acid at 80(R80G) (Yates et al. 2007) . A more recent study showed two other variants, rs22030199(R102G) and rs1047286 (P314L) also associated with ARMD; the changes in sequences altered binding to pathogenic cells and other complement factors (Despriet et al. 2009 ).
Toll like receptors (TLR) are involved in mounting an immune response to a foreign pathogen. Thus far ones that have been implicated are Tlr7 which recognized single stranded DNA, Tlr4, recognizing lipopolysaccharide, and Tlr3 which recognizes double stranded RNA, the last has been found to have the most association with geographic atrophy in ARMD (Edwards et al. 2008; Yang et al. 2008) . It is theorized that intracellular transmission of viral transcripts may activate Tlr3 and trigger inflammatory cascades leading to apoptosis and cell death of the RPE (Edwards et al. 2008) . The phe variation of this receptor suppresses dsRNA mediated atrophy by inducing less apoptosis than the Leu-Leu variant (Yang et al. 2008) . While there is no direct association between variation in Tlr3 to CNV, recent studies have shown that siRNA therapy suppresses CNV via Tlr3, showing that there may be a role of Tlr3 activation in reducing CNV . Table 3 summarizes factors involved in modulating retinal angiogenesis.
Conclusion
Over the past decade, novel markers of neovascularization have been identified, both at a molecular and genetic levels, consequently leading our understanding of the molecular mechanisms involved in ocular neovascularization to new heights. Stemming from better insight into the complex interplay of molecules in ocular angiogenesis, we believe that a multi-faceted approach to retarding or curbing NV is needed; targeting an array of biomolecules and modulating multiple signalling cascades holds promise for efficacious control of NV. Of late, gene therapy has received increasing attention from scientists around the world. We believe that the answer may lie in manipulating transcription factors and alternative splicing of putative genes involved in ocular NV, tipping the microenvironment to an anti-angiogenic state. We believe that through techniques in gene therapy, alternative splicing and RNA interference, we may meet with greater success in restoring ocular 'angiogenic privilege'.
